High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Pia Roering und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Institute of Biomedicine and FICAN West Cancer Centre, Faculty of Medicine, University of Turku, Turku, Finland; Turku Docto…. Hauptthemen laut MEDLINE: Polycomb Repressive Complex 1, Cystadenocarcinoma, Serous, Ovarian Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helsingin ja Uudenmaan Sairaanhoitopiiri, Cancer Foundation Finland, Finnish Cultural Foundation.
Abstract (Originalsprache)
OBJECTIVE: Tubo-ovarian high-grade serous carcinoma (HGSC) has a poor prognosis due to limited treatment options, therapy resistance, and high recurrence rates. One proposed mechanism underlying treatment failure is the survival of cancer stem cells (CSCs) following chemotherapy. In previous in vitro studies, we identified ALDH1A1, SOX2, MYC, and BMI1 as putative CSC markers, with increased expression linked to platinum resistance. This study aimed to evaluate the expression and prognostic relevance of these four markers in diagnostic, treatment-naïve HGSC tissue specimens. METHODS: We performed immunohistochemistry (IHC) on adnexal and extrapelvic samples from patients with stage III-IV HGSC. The expression levels of ALDH1A1, SOX2, MYC and BMI1 were manually scored and correlated with clinical parameters, including platinum-free interval (PFI) and overall survival (OS). Significant findings were validated with RNA in situ hybridization scoring, using an AI-assisted image analysis tool developed in this project. RESULTS: We found that all four proteins are widely expressed across tumor samples. High MYC and high BMI1 protein expression are each significantly associated with reduced PFI and OS. Higher expression levels are noted in extrapelvic tumor sites as compared to adnexal. In multivariable analysis, BMI1 expression remains an independent predictor of poor outcome. The significance of BMI1 as a prognostic marker is further demonstrated by RNA-ISH analysis, again showing independent association with outcome. CONCLUSIONS: Our findings highlight BMI1 as a clinically applicable prognostic marker in HGSC and suggests its potential as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Institute of Biomedicine and FICAN West Cancer Centre, Faculty of Medicine, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine (TuDMM), Faculty of Medicine, Univer…
- Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki Universit…
- Aiforia Technologies Plc, Helsinki, Finland.
- Department of Pathology, University of Helsinki and HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.
- Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Pathology, Institute of Biomedicine and FICAN West Cancer Centre, Faculty of Medicine, University of Turku, Turku, Finland.
Förderung
- Helsingin ja Uudenmaan Sairaanhoitopiiri
- Cancer Foundation Finland
- Finnish Cultural Foundation
- Southwest Finland Fund
- Horizon Europe
- Horizon 2020 Framework Programme
- University of Turku
- Ida Montinin Saatio
Zitieren
APA
Roering, P., Csellar, L., Blom, S., Raineva, I., Colangelo, K., Hänninen, S., Laury, A. R., Heuser, V. D., & Carpén, O. (2026). High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101332
Vancouver
Roering P, Csellar L, Blom S, Raineva I, Colangelo K, Hänninen S, et al. High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101332
BibTeX
@article{Roering2026,
author = {Roering, Pia and Csellar, Lilla and Blom, Sami and Raineva, Iona and Colangelo, Kia and Hänninen, Satu and Laury, Anna Ray and Heuser, Vanina D and Carpén, Olli},
title = {High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101332}
}
EUVIMED